Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
Tipo de estudo
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Niger J Clin Pract ; 24(6): 847-852, 2021 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-34121732

RESUMO

AIMS: We aimed to evaluate the effectivity and safety of botulinum toxin A (BT-A) to reduce sialorrhea in children with hypersalivation due to neurological diseases. METHODS: Patients who had a complaint of severe sialorrhea were included in the study. Drooling severity of the patients was evaluated using the classification of Thomas-Stonell and Greenberg. The frequency of aspiration before and after the procedure was recorded. The 24-hour saliva amount and mean duration of two consecutive aspirations were recorded. BT-A was injected into the bilateral parotid and submandibular glands by a otorhinolaryngologist under the guidance of ultrasound guidance (USG). RESULTS: When patients' mean drooling severity scores, drooling frequency scores, mean duration of two consecutive aspirations, and amount of saliva collected before and after procedure were compared, a statistical significance was observed. One-year hospital records before after and injection were examined and it was observed that after BT-A injection, hospital visits were statistically significantly low (P = 0.017). CONCLUSION: BT-A injection into salivary glands is well tolerated, is minimally invasive, has low complication rates and should be performed into both parotid and submandibular glands under USG. Although there is still no consensus on the ideal dose and frequency of injections, it is thought that a dose of 1U/kg/gland can be used with safety in pediatric age groups and the dimensions of the salivary glands and quantitative measurements of the amount of saliva should be utilized. Larger studies involving more patients are required in order to constitute a standard injection protocol.


Assuntos
Toxinas Botulínicas Tipo A , Sialorreia , Criança , Humanos , Glândula Parótida , Sialorreia/tratamento farmacológico , Sialorreia/etiologia , Glândula Submandibular , Resultado do Tratamento
2.
Opt Express ; 18(7): 6437-46, 2010 Mar 29.
Artigo em Inglês | MEDLINE | ID: mdl-20389667

RESUMO

We demonstrate a compact silicon photonic crystal Mach-Zehnder interferometer operating in the self-collimation regime. By tailoring the photonic band structure such as to produce self-collimated beams, it is possible to design beam splitters and mirrors and combine these to a 20 x 20 microm(2) format. With transmission spectroscopy we find a pronounced unidirectional optical output, the output ratio being as high as 25 at the self-collimation wavelength. Furthermore, the self-collimated beams and the unidirectionality are clearly observed in real space using near-field and far-field optical microscopy. Interpretation of the optical data is strongly supported by different types of simulations.

3.
Methods Find Exp Clin Pharmacol ; 32(5): 305-10, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-20664820

RESUMO

The effects of melatonin and quercetin on the contractile responses of cisplatin-treated rat detrusor smooth muscle were tested. Detrusor strips obtained from four separate rat groups (control, cisplatin, melatonin+cisplatin and quercetin+cisplatin) were mounted in 25 mL organ baths containing Krebs-Henseleit solution (KHS) at 37°C, continuously gassed with 95% O2 and 5% CO2. The vasoconstriction induced by acetylcholine (ACh) and potassium chloride (KCl) were compared within the groups. Furthermore, histopathological parameters such as edema, congestion, inflammatory cells, microvascular proliferation, fibrosis, eosinophil, mast cells and epithelial damage were noted. In routine experiments ACh and KCl triggered concentration-dependent contractions. Pretreatment with cisplatin increased the sensitivity but not the maximal response to ACh and KCl. In rats treated with melatonin or quercetin before cisplatin, the EC50 values, but not the maximal response, to both agents were significantly higher than in the cisplatin-treated (CII) group. Histopathological parameters such as edema, congestion, inflammatory cells, microvascular proliferation, fibrosis, eosinophil, mast cells and epithelial damage were all higher in the cisplatin-treated group than in the controls. Melatonin pretreatment significantly decreased mast cell numbers and epithelial damage when compared to cisplatin treatment alone but these effects were not recorded with quercetin pretreatment. These results demonstrate for the first time that melatonin can attenuate urinary bladder injury produced by cisplatin treatment.


Assuntos
Antineoplásicos/toxicidade , Antioxidantes/farmacologia , Cisplatino/toxicidade , Músculo Liso/efeitos dos fármacos , Bexiga Urinária/efeitos dos fármacos , Vasoconstritores/farmacologia , Acetilcolina/farmacologia , Animais , Feminino , Técnicas In Vitro , Melatonina/farmacologia , Contração Muscular/efeitos dos fármacos , Músculo Liso/fisiologia , Cloreto de Potássio/farmacologia , Quercetina/farmacologia , Ratos , Ratos Sprague-Dawley , Bexiga Urinária/fisiologia
4.
Indian J Exp Biol ; 48(12): 1188-93, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21250600

RESUMO

Cisplatin-based chemotherapy has a variety of vascular side effects. The aim of the present study was to evaluate the beneficial effect of melatonin and cisplatin on the alterations in vascular reactivity and structure of cisplatin-treated rats. Phenylephrine (PHE) and KCl-caused concentration-dependent contractions of rat aorta. Pretreatment with cisplatin increased the sensitivity but not the max response to PHE and KCl. In rats treated with melatonin or quercetin before cisplatin, the EC50 values, but not the maximal response to both agents were significantly higher than cisplatin-treated group. Compared to the control group, cisplatin-treatment significantly reduced the luminal area of the aorta. In melatonin and quercetin-treated aortas the luminal area values were significantly higher than cisplatin-treated group. The results demonstrate for the first time that melatonin and quercetin treatment may protect the aorta in cisplatin-based chemotherapy.


Assuntos
Antineoplásicos/farmacologia , Aorta Torácica/efeitos dos fármacos , Aorta Torácica/patologia , Cisplatino/farmacologia , Melatonina/farmacologia , Quercetina/farmacologia , Animais , Antioxidantes/farmacologia , Cardiotônicos/farmacologia , Feminino , Relaxamento Muscular/efeitos dos fármacos , Fenilefrina/farmacologia , Ratos , Ratos Sprague-Dawley
5.
Opt Lett ; 32(15): 2197-9, 2007 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-17671582

RESUMO

We demonstrate, for the first time to our knowledge, Raman lasing from stationary microdroplets on a superhydrophobic surface. In the experiments, glycerol-water microdroplets with radii in the 11-15 microm range were pumped at 532 nm with a pulsed, frequency-doubled Nd:YAG laser. Two distinct operation regimes of the microdroplets were observed: cavity-enhanced Raman scattering and Raman lasing. In the latter case, the Raman lasing signal was higher than the background by more than 30 dB. Investigation of the Raman spectra of various glycerol-water mixtures indicates that lasing occurs within the glycerol Raman band. Raman lasing was not sustained; rather, oscillation would occur in temporally separated bursts. Increasing the rate of convective cooling by nitrogen purging improved the lasing performance and reduced the average interburst separation from 2.3 to 0.4 s.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA